Lin K H, Winters A L, Lindahl R
Cancer Res. 1984 Nov;44(11):5219-26.
Significant changes in aldehyde dehydrogenase (ALDH) activity occur during rat hepatocarcinogenesis in vivo. An NADP-dependent tumor ALDH isozyme has been studied extensively. To better understand the nature, origin, and importance of this tumor-associated phenotypic change, we have examined the ALDH activity of five well-established rat hepatoma cell lines, H4-II-EC3, HTC, McA-RH7777, JM1, and JM2. HTC, JM1, and JM2 express the tumor ALDH phenotype, as indicated by elevated NADP-dependent, benzaldehyde-oxidizing activity, the appearance of new isozymes by electrophoresis, and characteristic histochemical localization of ALDH activity in situ. The tumor ALDH phenotype is not detected in McA-RH7777 cells. H4-II-EC3 has intermediate tumor ALDH activity. Thus, the 5 cell lines provide a spectrum of tumor ALDH activities representative of the range of activities seen in vivo. Benzo(a)pyrene, 3-methylcholanthrene, and phenobarbital induce hepatic ALDH activity after treatment in vivo. The ability of these compounds to induce ALDH in vitro was assessed in H4-II-EC3, McA-RH7777, HTC, JM1, and JM2. Treatment of cell cultures for 72 hr with 3-methylcholanthrene (1.0 mM) increases the NADP-dependent ALDH activity in H4-II-EC3 and McA-RH7777 cell lines up to 34- and 11-fold, respectively. Treatment with benzo(a)pyrene (1.0 mM) also increases the NADP-dependent ALDH activity in both lines up to 17- and 48-fold, respectively. Treatment with 3-methylcholanthrene or benzo(a)pyrene increases ALDH activity 2-fold in HTC and JM2 but does not increase NADP-dependent ALDH activity in JM1. Only marginal increases in NADP-dependent ALDH are observed after phenobarbital treatment in 4 of 5 cell lines. The induction of ALDH is blocked by actinomycin D, alpha-amanitin, and cycloheximide. These studies support our hypothesis that changes in ALDH activity observed in vivo are due to mutational events occurring in initiated cells. It appears that rat hepatoma cell lines will provide an in vitro model for studying genetic regulation of the tumor ALDH.
在大鼠体内肝癌发生过程中,醛脱氢酶(ALDH)活性会发生显著变化。一种依赖烟酰胺腺嘌呤二核苷酸磷酸(NADP)的肿瘤ALDH同工酶已得到广泛研究。为了更好地理解这种与肿瘤相关的表型变化的本质、起源及重要性,我们检测了5种成熟的大鼠肝癌细胞系H4-II-EC3、HTC、McA-RH7777、JM1和JM2的ALDH活性。HTC、JM1和JM2表现出肿瘤ALDH表型,表现为依赖NADP的苯甲醛氧化活性升高、电泳出现新的同工酶以及ALDH活性在原位的特征性组织化学定位。在McA-RH7777细胞中未检测到肿瘤ALDH表型。H4-II-EC3具有中等水平的肿瘤ALDH活性。因此,这5种细胞系提供了一系列肿瘤ALDH活性,代表了体内所见的活性范围。苯并(a)芘、3-甲基胆蒽和苯巴比妥在体内处理后可诱导肝脏ALDH活性。在H4-II-EC3、McA-RH7777、HTC、JM1和JM2中评估了这些化合物在体外诱导ALDH的能力。用3-甲基胆蒽(1.0 mM)处理细胞培养物72小时,可使H4-II-EC3和McA-RH7777细胞系中依赖NADP的ALDH活性分别增加至34倍和11倍。用苯并(a)芘(1.0 mM)处理也可使这两种细胞系中依赖NADP的ALDH活性分别增加至17倍和48倍。用3-甲基胆蒽或苯并(a)芘处理可使HTC和JM2中的ALDH活性增加2倍,但不会增加JM1中依赖NADP的ALDH活性。在5种细胞系中的4种中,苯巴比妥处理后仅观察到依赖NADP的ALDH有少量增加。放线菌素D、α-鹅膏蕈碱和环己酰亚胺可阻断ALDH的诱导。这些研究支持了我们的假设,即体内观察到的ALDH活性变化是由于起始细胞中发生的突变事件所致。看来大鼠肝癌细胞系将为研究肿瘤ALDH的基因调控提供一个体外模型。